You can buy a “longevity stack” in 30 seconds, but you can’t buy your way around biology. Today we sit down with Sergei Yakimov, a longevity-focused VC who has reviewed thousands of companies and only funded a handful, to unpack what actually earns conviction when real money and real outcomes are on the line.
We dig into the difference between evidence-based biotech and consumer longevity hype: why clinics, stem cell storefronts, peptide trends, and easy app plays often fail the defensibility and data test, and why serious teams obsess over focus, endpoints, and a realistic FDA and clinical trials roadmap. Sergei also explains why venture capital is still educated guesswork, why “smart money” can be an absurd label, and how “fake it till you make it” collapses once new data packages have to survive external scrutiny.
Then we go bigger: the influencer marketing engine and the human craving for shortcuts, why “aging is a disease” works as a catchy narrative but breaks down under measurement and trial design, and a more practical framework for longevity that targets the barriers that cause premature death disease by disease. We also get hands-on with what helps right now, from biomarker tracking to at-home blood testing that removes friction, plus a rapid-fire filter on resveratrol, NMN, senolytics, and plasma exchange.
If you care about healthspan, biotech investing, and cutting through longevity misinformation, hit subscribe, share this with one person who loves a shortcut, and leave a review with the single idea you’re changing after listening.
Podden och tillhörande omslagsbild på den här sidan tillhör
Brent Wallace. Innehållet i podden är skapat av Brent Wallace och inte av,
eller tillsammans med, Poddtoppen.
